Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
Financial Results for the year Ended December 31, 2023
截至2023年12月31日止年度的財務業績
As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million. The Company believes that its existing cash resources will be sufficient to meet its projected operating requirements through the second quarter of 2025, which includes the capital required to fund our ongoing operations, including R&D, the completion of the Phase 1 PK study related to our new generation platform and the GLP-2/OXM collaborative research we are conducting with OPKO.
截至2023年12月31日，Entera的現金及現金等價物爲1,100萬美元。該公司認爲，其現有現金資源將足以滿足其到2025年第二季度的預計運營需求，其中包括爲我們的持續業務提供資金所需的資金，包括研發、與我們的新一代平台相關的第一階段PK研究的完成以及我們與OPKO進行的GLP-2/OXM合作研究。
Research and development expenses for the year ended December 31, 2023 were $4.5 million, as compared to $5.8 million for the year ended December 31, 2022. The decrease of $1.3 million was primarily due to a decrease of $1.5 million in pre-clinical activity and materials costs and a decrease of $0.6 million in employee compensation, including a one-time payment made to a former employee pursuant to the terms of his separation agreement. The decrease was partially offset by an increase of $0.8 million in clinical expenses for our Phase 1 PK study related to our new generation platform and new formulations for EB612.
截至2023年12月31日止年度的研發費用爲450萬美元，而截至2022年12月31日的年度爲580萬美元。減少130萬美元的主要原因是臨床前活動和材料成本減少了150萬美元，員工薪酬減少了60萬美元，包括根據離職協議條款向一名前僱員支付的一次性付款。與我們的新一代平台和 EB612 新配方有關的 1 期 PK 研究的臨床費用增加了 80 萬美元，部分抵消了這一下降。
General and administrative expenses for the year ended December 31, 2023 were $4.4 million, compared to $7.3 million for the year ended December 31, 2022. The decrease of $2.8 million was mainly attributable to a decrease of $1.1 million in employee compensation, including a one-time payment to our former employee pursuant to the terms of his separation agreement, a decrease of $0.8 million as part of a restructuring of professional fees and other advisor expenses, a decrease in Board fees of $0.2 million due to the Board's forfeiture of their fees for the third and fourth quarters of 2023 and a decrease of $0.7 million in D&O insurance costs.
截至2023年12月31日止年度的一般和管理費用爲440萬美元，而截至2022年12月31日的年度爲730萬美元。減少280萬美元的主要原因是員工薪酬減少了110萬美元，其中包括根據我們的前僱員離職協議條款向其一次性付款，專業費用和其他顧問費用重組的一部分減少了80萬美元，由於董事會沒收了2023年第三和第四季度的費用，董事會費用減少了20萬美元，D&D減少了70萬美元 O 保險費用。
Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.
截至2023年12月31日止年度的運營支出爲890萬美元，而截至2022年12月31日的年度爲1,300萬美元。
Net loss was $8.9 million, or $0.31 per ordinary share (basic and diluted), for the year ended December 31, 2023, as compared to $13.1 million, or $0.45 per ordinary share (basic and diluted), for the year ended December 31, 2022.
截至2023年12月31日止年度的淨虧損爲890萬美元，合每股普通股（基本和攤薄後）0.31美元，而截至2022年12月31日止年度的淨虧損爲1,310萬美元，合每股普通股（基本和攤薄後）0.45美元。
譯文內容由第三人軟體翻譯。